TGF-β-dependent suppressive function of Tregs requires wild-type levels of CD18 in a mouse model of psoriasis

Journal of Clinical Investigation

Volumn 118, Issue 7, 2008, Pages 2629-2639

  Wang, Honglin ^a   Peters, Thorsten ^a   Sindrilaru, Anca ^a   Kess, Daniel ^a   Oreshkova, Tsvetelina ^a   Yu, Xue Zhong ^b   Seier, Anne Maria ^a   Schreiber, Heike ^a   Wlaschek, Meinhard ^a   Blakytny, Robert ^a   Röhrbein, Jan ^a   Schulz, Guido ^a   Weiss, Johannes M ^a   Scharffetter Kochanek, Karin ^a  

^a UNIVERSITY OF ULM   (Germany)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA2 INTEGRIN; CD18 ANTIGEN; CD4 ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 7 RECEPTOR; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; AUTOIMMUNITY; CELL FUNCTION; CELL INTERACTION; CELL PROLIFERATION; CONTROLLED STUDY; DENDRITIC CELL; DISEASE SEVERITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PSORIASIS; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; WILD TYPE;

ADOPTIVE TRANSFER; ANIMAL STRUCTURES; ANIMALS; ANTIBODIES; ANTIGENS, CD18; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CELL COMMUNICATION; CELL PROLIFERATION; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; LYMPHOCYTE ACTIVATION; LYMPHOCYTE CULTURE TEST, MIXED; MICE; MICE, INBRED C57BL; MICE, INBRED STRAINS; MICE, MUTANT STRAINS; PSORIASIS; SKIN; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY; TRANSFORMING GROWTH FACTOR BETA1;

EID: 46749143803     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI34916     Document Type: Article

References (63)

1. Schon, M.P., and Boehncke, W.H. 2005. Psoriasis. N. Engl. J. Med. 352:1899-1912.
2. Gottlieb, A.B., and Bos, J.D. 2002. Recombinantly engineered human proteins: transforming the treatment of psoriasis. Clin Immunol 105:105-116.
3. Schon, M.P., Detmar, M., and Parker, CM. 1997. Murine psoriasis-like disorder induced by naive CD4+ T cells. Nat. Med. 3:183-188.
4. Sano, S., et al. 2005. Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat. Med. 11:43-49.
5. Conrad, C, et al. 2007. Alpha1beta1 integrin is crucial for accumulation of epidermal T cells and the development of psoriasis. Nat. Med. 13:836-842.
6. Gottlieb, S.L., et al. 1995. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat. Med. 1:442-447.
7. Owen, CM., and Harrison, P.V. 2000. Successful treatment of severe psoriasis with basiliximab, an interleukin-2 receptor monoclonal antibody. Clin. Exp. Dermatol. 25:195-197.
8. Morel, P., et al. 1992. Anti-CD4 monoclonal antibody therapy in severe psoriasis. J. Autoimmun. 5:465-477.
9. Sugiyama, H., et al. 2005. Dysfunctional blood and target tissue CD4+CD25high regulatory T cells in psoriasis: mechanism underlying unrestrained pathogenic effector T cell proliferation. J. Immunol. 174:164-173.
10. Brusko, T., et al. 2007. No alterations in the frequency of FOXP3+ regulatory T-cells in type 1 diabetes. Diabetes. 56:604-612.
11. Putheti, P., Pettersson, A., Soderstrom, M., Link, H., and Huang, Y. 2004. Circulating CD4+CD25+ T regulatory cells are not altered in multiple sclerosis and unaffected by disease-modulating drugs. J. Clin. Immunol. 24:155-161.
12. Ehrenstein, M.R., et al. 2004. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J. Exp. Med. 200:277-285.
13. Baecher-Allan, C, Brown, J.A., Freeman, G.J., and Hafler, D.A. 2001. CD4+CD25high regulatory cells in human peripheral blood. J. Immunol. 167:1245-1253.
14. Sakaguchi, S., et al. 2001. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol. Rev. 182:18-32.
15. Fontenot, J.D., Gavin, M.A., and Rudensky, A.Y. 2003. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat. Immunol. 4:330-336.
16. Seddiki, N., et al. 2006. Persistence of naive CD45RA+ regulatory T cells in adult life. Blood. 107:2830-2838.
17. Seddiki, N., et al. 2006. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J. Exp. Med. 203:1693-1700.
18. Liu, W., et al. 2006. CD 127 expression inversely correlates with FoxP3 and suppressive function of human CD4+Treg cells. J. Exp. Med. 203:1701-1711.
19. Hartigan-O'Connor, D.J., Poon, C, Sinclair, E., and McCune, J.M. 2007. Human CD4+ regulatory T cells express lower levels of the IL-7 receptor alpha chain (CD127), allowing consistent identification and sorting of live cells. J. Immunol. Methods. 319:41-52.
20. Wilson, R.W., et al. 1993. Gene targeting yields a CD18-mutant mouse for study of inflammation. J. Immunol. 151:1571-1578.
21. Bullard, D.C, et al. 1996. A polygenic mouse model of psoriasiform skin disease in CD18-deficient mice. Proc. Natl. Acad. Sci. U. S. A. 93:2116-2121.
22. Kess, D., et al. 2003. CD4+ T cell-associated pathophysiology critically depends on CD18 gene dose effects in a murine model of psoriasis. J. Immunol. 171:5697-5706.
23. Wang, H., et al. 2006. Activated macrophages are essential in a murine model for T cell-mediated chronic psoriasiform skin inflammation. J. Clin. Invest. 116:2105-2114.
24. Hynes, R.O. 1987. Integrins: a family of cell surface receptors. Cell. 48:549-554.
25. Griffiths, C.E., Railan, D., Gallatin, W.M., and Cooper, K.D. 1995. The ICAM-3/LFA-1 interaction is critical for epidermal Langerhans cell alloantigen presentation to CD4+ T cells. Br. J. Dermatol. 133:823-829.
26. Gencik, M., et al. 2000. The association of CD18 alleles with anti-myeloperoxidase subtypes of ANCA-associated systemic vasculitides. Clin. Immunol. 94:9-12.
27. Meller, S., et al. 2001. Novel SNPs in the CD 18 gene validate the association with MPO-ANCA+ vasculitis. Genes Immun. 2:269-272.
28. van de Kerkhof, P.C, and Weemaes, CM. 1990. Skin manifestations in congenital deficiency of leucocyte-adherence glycoproteins (CDLG). Br. J. Dermatol. 123:395-401.
29. Tomfohrde, J., et al. 1994. Gene for familial psoriasis susceptibility mapped to the distal end of human chromosome 17q. Science. 264:1141-1145.
30. Van Seventer, G.A., Shimizu, Y., Horgan, K.J., and Shaw, S. 1990. The LFA-1 ligand ICAM-1 provides an important costimulatory signal for T cell receptor-mediated activation of resting T cells. J. Immunol. 144:4579-4586.
31. Shier, P., et al. 1996. Impaired immune responses toward alloantigens and tumor cells but normal thymic selection in mice deficient in the beta2 integrin leukocyte function-associated antigen-1. J. Immunol. 157:5375-5386.
32. Damle, N.K., Klussman, K., and Aruffo, A. 1992. Intercellular adhesion molecule-2, a second counter-receptor for CD11a/CD18 (leukocyte function-associated antigen-1), provides acostimulatory signal for T-cell receptor-initiated activation of human T cells. J. Immunol. 148:665-671.
33. Gavin, M.A., Clarke, S.R., Negrou, E., Gallegos, A., and Rudensky, A. 2002. Homeostasis and anergy of CD4+CD25+ suppressor T cells in vivo. Nat. Immunol. 3:33-41.
34. Takahashi, T., et al. 1998. Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int. Immunol. 10:1969-1980.
35. Yamazaki, S., et al. 2006. Effective expansion of alloantigen-specific Foxp3+ CD25+ CD4+ regulatory T cells by dendritic cells during the mixed leukocyte reaction. Proc. Natl. Acad. Sci. U. S. A. 103:2758-2763.
36. Yamazaki, S., et al. 2003. Direct expansion of functional CD25+ CD4+ regulatory T cells by antigen-processing dendritic cells. J. Exp. Med. 198:235-247.
37. Cozzo, C., Larkin,J., 3rd and Caton, A.J. 2003. Cutting edge: self-peptides drive the peripheral expansion of CD4+CD25+ regulatory T cells. J. Immunol. 171:5678-5682.
38. Kretschmer, K., et al. 2005. Inducing and expanding regulatory T cell populations by foreign antigen. Nat. Immunol. 6:1219-1227.
39. Tang, Q., et al. 2006. Visualizing regulatory T cell control of autoimmune responses in nonobese diabetic mice. Nat. Immunol. 7:83-92.
40. Anderson, D.C, Miller, L.J., Schmalstieg, F.C, Rothlein, R., and Springer, T.A. 1986. Contributions of the Mac-1 glycoprotein family to adherence-dependent granulocyte functions: structure-function assessments employing subunit-specific monoclonal antibodies. J. Immunol. 137:15-27.
41. Piccirillo, C.A., et al. 2002. CD4+CD25+ Regulatory T cells can mediate suppressor function in the absence of transforming growth factor beta1 production and responsiveness. J. Exp. Med. 196:237-246.
42. Nakamura, K., et al. 2004. TGF-beta 1 plays an important role in the mechanism of CD4+CD25+ regulatory T cell activity in both humans and mice. J. Immunol. 172:834-842.
43. Marski, M., Kandula, S., Turner, J.R, and Abraham, C 2005. CD18 is required for optimal development and function of CD4+CD25+ T regulatory cells. J. Immunol. 175:7889-7897
44. Tarbell, K.V., Yamazaki, S., Olson, K., Toy, P., and Steinman, R.M. 2004. CD25+ CD4+ T cells, expanded with dendritic cells presenting a single autoantigenic peptide, suppress autoimmune diabetes. J. Exp. Med. 199:1467-1477.
45. Salomon, B., et al. 2000. B7/CD28costimulationis essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity. 12:431-440.
46. Tang, Q., et al. 2003. Cutting edge: CD28 controls peripheral homeostasis of CD4+CD25+ regulatory T cells. J. Immunol. 171:3348-3352.
47. Judkowski, V., et al. 2001. Identification of MHC class II-restricted peptide ligands, including a glutamic acid decarboxylase 65 sequence, that stimulate diabetogenic T cells from transgenic BDC2.5 nonobese diabetic mice. J. Immunol. 166:908-917.
48. Gaylor, M.L., and Duvic, M. 2004. Generalized pustular psoriasis following withdrawal of efalizumab. J. Drugs Dermatol. 3:77-79.
49. Sakaguchi, N., et al. 2003. Altered thymic T-cell selection due to a mutation of the ZAP-70 gene causes autoimmune arthritis in mice. Nature. 426:454-460.
50. Alarcon-Riquelme, M.E. 2003. A RUNX trio with a taste for autoimmunity. Nat. Genet. 35:299-300.
51. Ghoreschi, K., et al. 2003. Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease. Nat. Med. 9:40-46.
52. Asadullah, K., et al. 1998. IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: a new therapeutic approach. J. Clin. Invest. 101:783-794.
53. Read, S., Malmstrom, V.,andPowrie, F. 2000. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25+CD4+ regulatory cells that control intestinal inflammation. J. Exp. Med. 192:295-302.
54. Belghith, M., et al. 2003. TGF-[beta]-dependent mechanisms mediate restoration of self-tolerance induced by antibodies to CD3 in overt autoimmune diabetes. Nat. Med. 9:1202-1208.
55. + T cells. Nat. Med. 12:627-635.
56. Nakamura, K., Kitani, A., and Strober, W. 2001. Cell contact-dependent immunosuppression by CD4+CD25+ regulatory T Cells is mediated by cell surface-bound transforming growth factor beta. J. Exp. Med. 194:629-644.
57. Peng, Y., Laouar, Y., Li, M.O., Green, E.A., and Flavell, R.A. 2004. TGF-beta regulates in vivo expansion of Foxp3-expressing CD4+CD25+ regulatory T cells responsible for protection against diabetes. Proc. Natl. Acad. Sci. U. S. A. 101:4572-4577.
58. Shull, M.M., et al. 1992. Targeted disruption of the mouse transforming growth factor-[beta] 1 gene results in multifocal inflammatory disease. Nature. 359:693-699.
59. Kulkarni, A.B., et al. 1993. Transforming growth factor beta1 null mutation in mice causes excessive inflammatory response and early death. Proc. Natl. Acad. Sci. U. S. A. 90:770-774.
60. Ghiringhelli, F., et al. 2005. Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J. Exp. Med. 202:919-929.
61. Ishikawa, H.,et al. 2007. Inhibition of autoimmune diabetes by oral administration of anti-CD3 monoclonal antibody. Diabetes. 56:2103-2109.
62. Garba, M.L., and Frelinger, J.A. 2001. Intracellular cytokine staining forTGF-[beta]. J. Immunol. Methods. 258:193-198.
63. Venken, K., et al. 2007. A CFSE based assay for measuring CD4+CD25+ regulatory T cell mediated suppression of auto-antigen specific and polyclonal T cell responses. J. Immunol. Methods. 322:1-11.